Article

Therapeutic Targeting Tongue Squamous Cell Carcinoma via ICAM1 Antibody-Drug Conjugates in Preclinical Models

2023-09-21

Abstract excerpt

<title>Abstract</title> <p>To date, the treatment options for metastatic and recurrent tongue squamous cell carcinoma (TSCC) remain limited due to the lack of effective drug targets and therapeutics. Here we report the identification of ICAM1 as a TSCC target candidate for the development of antibody-drug conjugates (ADC), an emerging class of targeted therapeutics. We first performed an unbiased and quantitative...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5bbbc4c7-55bd-59c0-9a07-e4a755f79f48
DOI: 10.21203/rs.3.rs-3353522/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 9 closest

Therapeutic Targeting Tongue Squamous Cell Carcinoma via ICAM1 Antibody-Drug Conjugates in Preclinical ModelsDOI 10.21203/rs.3.rs-3353522/v1Read

Inhibition of ICAM2 induces radiosensitisation in oral squamous cell carcinoma cellsSemantic proximity Read

CAR T cells targeting Nectin-4 safely overcome resistance to anti-Nectin-4 antibody-drug conjugate in solid tumorsSemantic proximity Read

Muc1 ImmunotherapySemantic proximity Read

Development of antibody-drug conjugates targeting L1CAM to treat metastatic cancerSemantic proximity Read

ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.Semantic proximity Read

Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transportersSemantic proximity Read

TTI-101 targets STAT3/c-Myc signaling pathway to suppress cervical cancer progression: an integrated experimental and computational analysisSemantic proximity Read

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.Semantic proximity Read

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A InhibitorsSemantic proximity Read